Latest Strategic Partnership News

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Volt Group Limited reports a 38% surge in EcoQuip revenue alongside steady progress in zero-emission technologies, positioning itself strongly in the clean energy transition.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Vection Technologies reports its first positive underlying EBITDA alongside a 22% pro-forma revenue increase, driven by major defence contracts and AI integration. The company’s strategic acquisition and sector diversification set the stage for sustainable growth in FY26.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.